{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:10:36Z","timestamp":1780387836581,"version":"3.54.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The impact of disease-modifying therapies (DMTs) on chronic pain in multiple sclerosis (MS) is poorly understood. Preclinical research suggests that modulation of sphingosine-1-phosphate pathways involved in inflammation and central sensitization could exert analgesic effects alongside MS relapse prevention, but more clinical data are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare pain phenotypes, severity, and treatment regimens in persons living with MS using sphingosine-1-phosphate receptor (S1PR) modulators versus other DMTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a secondary analysis of cross-sectional data from a nationwide MS survey. Univariate analyses (t- and chi-squared tests) were used to examine associations among DMT class, demographics, disability severity, MS duration, pain outcomes (including pain phenotype [via the painDETECT Questionnaire for neuropathic pain and the American College of Rheumatology Fibromyalgia Survey for nociplastic pain], intensity, and interference comorbidities (PROMIS surveys), and analgesic therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 731 participants, 82 used S1PR modulators. S1PR users were younger (48.02 vs 52.51 years), but other characteristics were similar. After adjustment for age, pain types were similar in both groups. Among those with nociplastic pain, S1PR patients reported lower pain intensity than did those on other DMTs (P\u2009=\u2009.02).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with other DMTs, S1PR modulators are associated with lower pain intensity in patients with MS with nociplastic pain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/pm\/pnag008","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:34:13Z","timestamp":1768566853000},"page":"689-695","source":"Crossref","is-referenced-by-count":0,"title":["Pain outcomes in persons with multiple sclerosis receiving S1PR modulators: a cross-sectional study"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2758-8265","authenticated-orcid":false,"given":"Salvador","family":"Sierra","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Michigan , Ann Arbor, MI,","place":["United States"]},{"name":"Department of Anesthesiology, University of Virginia , Charlottesville, VA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3664-3898","authenticated-orcid":false,"given":"Anna L","family":"Kratz","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0680-7828","authenticated-orcid":false,"given":"Tiffany J","family":"Braley","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"2026060203511532700_pnag008-B1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"2026060203511532700_pnag008-B2","first-page":"1","volume-title":"Multiple Sclerosis","author":"Javalkar","year":"2016"},{"key":"2026060203511532700_pnag008-B3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1191\/1352458503ms939oa","article-title":"Chronic pain in a large community sample of persons with multiple sclerosis","volume":"9","author":"Ehde","year":"2003","journal-title":"Mult Scler"},{"key":"2026060203511532700_pnag008-B4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.apmr.2008.10.019","article-title":"Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors","volume":"90","author":"Hirsh","year":"2009","journal-title":"Arch Phys Med Rehabil"},{"key":"2026060203511532700_pnag008-B5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/1352458506071346","article-title":"The scope and nature of pain in persons with multiple sclerosis","volume":"12","author":"Ehde","year":"2006","journal-title":"Mult Scler"},{"key":"2026060203511532700_pnag008-B6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nrl.2010.07.014","article-title":"Analysis of the pain in multiple sclerosis patients","volume":"26","author":"Grau-L\u00f3pez","year":"2011","journal-title":"Neurolog\u00eda"},{"key":"2026060203511532700_pnag008-B7","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1097\/j.pain.0000000000002136","article-title":"Characterizing chronic pain phenotypes in multiple sclerosis: a nationwide survey study","volume":"162","author":"Kratz","year":"2021","journal-title":"Pain"},{"key":"2026060203511532700_pnag008-B8","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing-remitting multiple sclerosis","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"key":"2026060203511532700_pnag008-B9","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"2026060203511532700_pnag008-B10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41582-021-00519-3","article-title":"The multiple sclerosis prodrome","volume":"17","author":"Makhani","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"2026060203511532700_pnag008-B11","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity\u2013free relapsing multiple sclerosis","volume":"85","author":"Cree","year":"2019","journal-title":"Ann Neurol"},{"key":"2026060203511532700_pnag008-B12","doi-asserted-by":"crossref","first-page":"e979","DOI":"10.1212\/NXI.0000000000000979","article-title":"Evolution of brain volume loss rates in early stages of multiple sclerosis","volume":"8","author":"Uher","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026060203511532700_pnag008-B13","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol"},{"key":"2026060203511532700_pnag008-B14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s13311-017-0565-4","article-title":"Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis","volume":"14","author":"Chaudhry","year":"2017","journal-title":"Neurotherapeutics"},{"key":"2026060203511532700_pnag008-B15","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1080\/14656566.2018.1540592","article-title":"Ozanimod for the treatment of relapsing remitting multiple sclerosis","volume":"19","author":"Rasche","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2026060203511532700_pnag008-B16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41589-021-00930-3","article-title":"Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism","volume":"18","author":"Xu","year":"2022","journal-title":"Nat Chem Biol"},{"key":"2026060203511532700_pnag008-B17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","article-title":"The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis","volume":"30","author":"Hunter","year":"2016","journal-title":"CNS Drugs"},{"key":"2026060203511532700_pnag008-B18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jpain.2019.02.007","article-title":"Activation of sphingosine-1-phosphate receptor 1 in the spinal cord produces mechanohypersensitivity through the activation of inflammasome and IL-1\u03b2 pathway","volume":"20","author":"Doyle","year":"2019","journal-title":"J Pain"},{"key":"2026060203511532700_pnag008-B19","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.0b013e31820d5ec1","article-title":"Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation","volume":"76","author":"Hla","year":"2011","journal-title":"Neurology"},{"key":"2026060203511532700_pnag008-B20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/glia.23558","article-title":"Lipid transporter Spns2 promotes microglia pro-inflammatory activation in response to amyloid-beta peptide","volume":"67","author":"Zhong","year":"2019","journal-title":"Glia"},{"key":"2026060203511532700_pnag008-B21","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.neuropharm.2006.11.010","article-title":"Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors","volume":"52","author":"Osinde","year":"2007","journal-title":"Neuropharmacology"},{"key":"2026060203511532700_pnag008-B22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ana.22186","article-title":"Fingolimod provides long-term protection in rodent models of cerebral ischemia","volume":"69","author":"Wei","year":"2011","journal-title":"Ann Neurol"},{"key":"2026060203511532700_pnag008-B23","doi-asserted-by":"crossref","first-page":"e2965","DOI":"10.1002\/brb3.2965","article-title":"Fingolimod ameliorates chronic experimental autoimmune neuritis by modulating inflammatory cytokines and Akt\/mTOR\/NF-\u03baB signaling","volume":"13","author":"Feng","year":"2023","journal-title":"Brain Behav"},{"key":"2026060203511532700_pnag008-B24","doi-asserted-by":"crossref","first-page":"110165","DOI":"10.1016\/j.neuropharm.2024.110165","article-title":"Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P1 receptor\u2013mediated G-protein activation in a mouse model of sciatic nerve injury","volume":"261","author":"Pondelick","year":"2024","journal-title":"Neuropharmacology"},{"key":"2026060203511532700_pnag008-B25","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1185\/030079906X132488","article-title":"painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain","volume":"22","author":"Freynhagen","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2026060203511532700_pnag008-B26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2026060203511532700_pnag008-B27","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"2026060203511532700_pnag008-B28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/j.pain.0000000000001106","article-title":"Fingolimod reduces neuropathic pain behaviors in a mouse model of multiple sclerosis by a sphingosine-1 phosphate receptor 1\u2013dependent inhibition of central sensitization in the dorsal horn","volume":"159","author":"Doolen","year":"2018","journal-title":"Pain"},{"key":"2026060203511532700_pnag008-B29","doi-asserted-by":"crossref","first-page":"10\u2009557","DOI":"10.1073\/pnas.1820466116","article-title":"Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain","volume":"116","author":"Chen","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026060203511532700_pnag008-B30","doi-asserted-by":"crossref","first-page":"e55255","DOI":"10.1371\/journal.pone.0055255","article-title":"Sphingosine 1-phosphate mediates hyperalgesia via a neutrophil-dependent mechanism","volume":"8","author":"Finley","year":"2013","journal-title":"PLoS One"},{"key":"2026060203511532700_pnag008-B31","doi-asserted-by":"crossref","first-page":"109029","DOI":"10.1016\/j.neuropharm.2022.109029","article-title":"Acetaminophen and pregabalin attenuate central sensitization in rodent models of nociplastic widespread pain","volume":"210","author":"Yajima","year":"2022","journal-title":"Neuropharmacology"},{"key":"2026060203511532700_pnag008-B32","doi-asserted-by":"crossref","first-page":"795574","DOI":"10.3389\/fimmu.2021.795574","article-title":"Risk for cardiovascular adverse events associated with sphingosine-1-phosphate receptor modulators in patients with multiple sclerosis: insights from a pooled analysis of 15 randomised controlled trials","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"2026060203511532700_pnag008-B33","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol"},{"key":"2026060203511532700_pnag008-B34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jns.2016.11.067","article-title":"Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis","volume":"372","author":"Boeschoten","year":"2017","journal-title":"J Neurol Sci"},{"key":"2026060203511532700_pnag008-B35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1037\/rep0000027","article-title":"Pain affects depression through anxiety, fatigue, and sleep in multiple sclerosis","volume":"60","author":"Amtmann","year":"2015","journal-title":"Rehabil Psychol"},{"key":"2026060203511532700_pnag008-B36","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jpainsymman.2008.08.004","article-title":"Symptom cluster as a predictor of physical activity in multiple sclerosis: preliminary evidence","volume":"38","author":"Motl","year":"2009","journal-title":"J Pain Symptom Manage"},{"key":"2026060203511532700_pnag008-B37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/j.pain.0000000000001429","article-title":"The association between multiple sclerosis and pain medications","volume":"160","author":"Burkill","year":"2019","journal-title":"Pain"},{"key":"2026060203511532700_pnag008-B38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2377-13-37","article-title":"Validation of Patient Determined Disease Steps (PDDS) scale scores in persons with multiple sclerosis","volume":"13","author":"Learmonth","year":"2013","journal-title":"BMC Neurol"},{"key":"2026060203511532700_pnag008-B39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/13524585231213230","article-title":"The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022","volume":"30","author":"Zhao","year":"2024","journal-title":"Mult Scler"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/painmedicine\/advance-article-pdf\/doi\/10.1093\/pm\/pnag008\/66487138\/pnag008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/27\/6\/689\/66487138\/pnag008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/27\/6\/689\/66487138\/pnag008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:51:29Z","timestamp":1780386689000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/27\/6\/689\/8432259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,1,20]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnag008","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,1,20]]}}}